Established in 2011, Diagnomics is one of the first Next Generation Sequencing (NGS)-based genomics companies on the West Coast of the United States. It is providing sophisticated solutions for personalized medicine and next generation healthcare.

Diagnomics has a highly qualified team of scientists including early pioneers in sequencing the human genome. Additionally, Diagnomics has cutting edge genome presentation software as well as genome discovery expertise to guide the development of novel diagnostic tools and new therapeutic targets.

Diagnomics’ founders actually performed the first human genome re-sequencing project and completed sequencing of one of the first personal human genomes. Their findings were published in top peer-reviewed journals, including Science. In addition, the team has successfully sequenced and analyzed many normal and diseased human genomes including individuals with various cancers and rare genetic diseases.

Scientific advancement in genomic medicine is enabling to diagnose diseases earlier and more precisely. That in turn, allows to predict health risk more accurately, and to ultimately achieve a truly personalized treatment. In fact, several recent technology breakthroughs in next generation sequencing have accelerated the adaptation of personal genomics, and it is expected that the cost to do whole genome sequencing will fall to less than $1,000 within the next few years. Accurate and affordable sequencing coupled with an advanced genome analysis, will ultimately usher in a new era of personalized medicine.